OncRef

Clinical Trial: NCT05182385

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Goethe University
Information Provided By:Goethe University
Last Update Posted:2025-07-25

Study Overview

Brief Summary

This study is designed to determine the feasibility, safety, tolerability and maximum tolerated dose of Venetoclax in combination with Blinatumomab and to evaluate the response in patients treated with the combination of Venetoclax and Blinatumomab in in patients with hematological relapse or molecular relapse.

Official Title

An Open Label, Phase I/II Study of Venetoclax in Addition to Blinatumomab Immunotherapy in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Conditions

ALL, Recurrent, Adult

Intervention / Treatment

  • Drug: Blinatumomab
  • Drug: Venetoclax

Other Study ID Numbers

  • GMALL-BLIVEN
  • 2021-001384-25

Start Date (Actual)

2021-12-15

Primary Completion Date (Estimated)

2026-04-30

Study Completion Date (Estimated)

2026-04-30

Enrollment (Actual)

30

Study Type

Interventional

Phase

Phase 1, Phase 2